Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers

Pre-clinical studies have shown that injection of allogeneic T cells primed against a single minor histocompatibility antigen (MiHA) could cure hematologic cancers (HC) without causing any toxicity to the host. However, translation of this approach in humans has been hampered by the paucity of molec...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2016-06, Vol.30 (6), p.1344-1354
Hauptverfasser:	Granados, D P, Rodenbrock, A, Laverdure, J-P, Côté, C, Caron-Lizotte, O, Carli, C, Pearson, H, Janelle, V, Durette, C, Bonneil, E, Roy, D C, Delisle, J-S, Lemieux, S, Thibault, P, Perreault, C
Format:	Artikel
Sprache:	eng
Schlagworte:	45/90 631/250/1854/2812 631/250/580 631/67/1059/2325 631/67/1990/283/1897 631/92/436/434 692/699/1541/1990 82/58 Antigens Blood cancer Blood diseases Cancer Cancer Research Care and treatment Cells, Cultured Critical Care Medicine Female Genetic aspects Graft versus host disease Haplotypes Health aspects Hematologic Neoplasms - therapy Hematology Histocompatibility antigen HLA Histocompatibility antigens HLA histocompatibility antigens HLA-A2 Antigen HLA-B44 Antigen Humans Immunology Immunotherapy Immunotherapy - methods Intensive Internal Medicine Leukemia Lymphocytes Lymphocytes T Male Medicine Medicine & Public Health Methods Minor histocompatibility antigens Minor Histocompatibility Antigens - therapeutic use Mutation Oncology original-article Patients Peptides Proteogenomics - methods Proteomics Toxicity Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!